Arvinas, Inc. (ARVN) financial statements (2021 and earlier)

Company profile

Business Address 395 WINCHESTER AVE
NEW HAVEN, CT 06511
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments689249243263281191159
Cash and cash equivalents58889223691211
Short-term investments100160221227272178148
Receivables8644651
Other undisclosed current assets6333443
Total current assets:703258250270291200163
Noncurrent Assets
Operating lease, right-of-use asset222322 
Property, plant and equipment12121110876
Other noncurrent assets0000000
Other undisclosed noncurrent assets      2
Total noncurrent assets:141413121199
TOTAL ASSETS:717272263282302209172
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities261710101295
Accounts payable7523521
Accrued liabilities191277864
Deferred revenue222123222020 
Debt  11110
Contract with customer, liability15
Other undisclosed current liabilities11    1
Total current liabilities:49403433332921
Noncurrent Liabilities
Long-term debt and lease obligation3344442
Long-term debt, excluding current maturities2222222
Operating lease, liability112222 
Liabilities, other than long-term debt23242734384231
Deferred revenue232427343842 
Contract with customer, liability31
Other undisclosed noncurrent liabilities      2
Total noncurrent liabilities:26273138424635
Total liabilities:75676571757556
Stockholders' equity
Stockholders' equity attributable to parent642205198212227134117
Common stock0000000
Additional paid in capital1,134654616607599485450
Accumulated other comprehensive income (loss)112(1)000
Accumulated deficit(492)(450)(420)(394)(373)(352)(334)
Total stockholders' equity:642205198212227134117
TOTAL LIABILITIES AND EQUITY:717272263282302209172

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:28665304
Operating expenses(45)(39)(32)(30)(28)(25)(22)
Operating income (loss):(43)(32)(26)(23)(23)6(18)
Nonoperating income2112211
Investment income, nonoperating1111111
Other nonoperating income1000100
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Income (loss) from continuing operations before equity method investments, income taxes:(42)(31)(25)(22)(21)7(17)
Loss from equity method investments     (25) 
Loss before gain (loss) on sale of properties:(42)(31)(25)(22)(21)(18)(17)
Other undisclosed net income0  00  
Net loss:(42)(31)(25)(22)(21)(18)(17)
Other undisclosed net income attributable to parent 00  00
Net loss available to common stockholders, diluted:(42)(31)(25)(22)(21)(18)(17)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(42)(31)(25)(22)(21)(18)(17)
Comprehensive loss:(42)(31)(25)(22)(21)(18)(17)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)(1)2(1)(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(42)(31)(23)(22)(21)(18)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: